Why did the Functional Genomics and Translational Biology (FGTB) Council change its name to the Genomic and Precision Medicine Council?
The name was changed effective February 1, 2018 because our council recognized that our scientific missions and constituency had expanded and diversified to include leaders in clinical genetics including genetic counseling; broader discovery sciences in the omics arena including metabolomics and proteomics; implementation science for genomics and other omics disciplines; and computation biology and quantitative sciences, all with an overall goal of more precise cardiovascular risk prediction and prevention to improve health.

Who can benefit from the Genomic and Precision Medicine Council?
Our membership includes a broad and diverse group of individuals across genomics, other omics including the microbiome, computation and quantitative sciences, clinical genetics, and precision medicine. We are closely aligned scientifically and administratively with the American Heart Association (AHA) journal Circulation: Genomic and Precision Medicine and the AHA’s Institute for Precision Cardiovascular Medicine.

What is the vision of the Genomic and Precision Medicine Council?
The mission of the AHA Genomic and Precision Medicine (GPM) Council is to advance discovery and translation in genetics, genomics, metabolomics, proteomics and any other technology into precision cardiovascular medicine, using inter-disciplinary expertise with the ultimate goal of precise risk prediction, prevention and treatment. Integral to the American Heart Association operation, the GPM Council provides a premier inter-disciplinary forum promoting and integrating new knowledge from molecules to populations in translational cardiovascular science and precision medicine.

Where do I refer individuals who would like more information?
The council website at professional.heart.org/gpmcouncil will have more information. Also, other materials about the name change will be available.